MENU
ALGS
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Aligos Therapeutics (ALGS) Ownership - Who owns Aligos Therapeutics?
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company... Show more
Profile
Industry
N/A
Address
One Corporate Drive
Phone
+1 800 466-6059
Employees
66
Web
https://www.aligos.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
36.99M
P/E Ratio
N/A
Total Cash
137.86M
Projected Growth
N/A
Total Debt
7.87M
Revenue
3.27M
Risk (Beta)
2.47
Dividend Yield
N/A
Total Cash/Share
22.55
Total Debt/Equity
N/A
Revenue/Share
0.48 USD as % of share price
Fundamentals
ALGS
Capitalization
37M
P/E Ratio
N/A
Risk (Beta)
2.47
Dividend Yield
N/A
Total Cash
138M
Total Cash/Share
22.55
Total Debt
7.87M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.48%
Revenue
3.27M
ROE
N/A
Book Value
116M
P/B Ratio
0.32
Cash Flow
N/A
Earnings
-10.24
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
9K
Current Ratio
7.56
Current Revenue Per Employee
4442.86
Dividends Per Share - Security
N/A
EBITDA
-83.89M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-38.23
Shares Held By Institutions
65.3M
Shares Outstanding - Current
6.12M
Total Liabilities
34.3M
Total Volume MTD
N/A
Value
1
Gain YTD
-84.814
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
One Corporate Drive
Phone
+1 800 466-6059
Employees
66
Web
https://www.aligos.com